[1]
Williams, S. 2017. Revising the Guidance Document for Biosimilar Agents. Health Reform Observer – Observatoire des Réformes de Santé. 5, 1 (Apr. 2017). DOI:https://doi.org/10.13162/hro-ors.v5i1.2982.